poisar

Stocks · News reference

AbbVie Says Real-World Studies Show VRAYLAR Improved Depressive Symptoms In Bipolar I Depression, Adjunctive Major Depressive Disorder At Psych Congress 2026

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Sara Appino

    AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

    ABBVBMYCELGRMCKCAH
  2. Researchandmarkets.Com

    Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

    The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

    ABBVJNJPFENVSRHHBY